 | | Vol. 12.46 – 26 November, 2020 |
| |
|
|
| Investigators showed that the protein phosphatase 2A (PP2A) regulatory subunit PPP2R2B was a crucial determinant of anti-HER2 response. PPP2R2B was downregulated in a substantial subset of HER2+ breast cancers, which correlated with poor clinical outcome and resistance to HER2-targeted therapies.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that ULK1 deficiency induced an invasive phenotype of breast cancer cells under hypoxia and increases osteolytic bone metastasis.
[Autophagy] |
|
|
|
| Scientists combined a bioinformatics approach exploring both METABRIC and TCGA databases with CRISPR/Cas9-mediated depletion of the zinc finger E-box binding homeobox 1 (ZEB1) in claudin-low tumor cells or forced expression of ZEB1 in basal-like tumor cells, two TNBC subtypes, to demonstrate that ZEB1 represses DNA polymerase theta (POLθ) expression.
[Cancer Research] |
|
|
|
| Researchers report that Sperm-associated antigen 5 (SPAG5) is a direct target of miR-10b-3p, and its aberrantly high expression associates with poor disease-free survival in two large cohorts of breast cancer patients. SPAG5 depletion strongly impaired cancer cell cycle progression, proliferation, and migration.
[Cell Death & Differentiation] |
|
|
|
| Scientists studied Zinc-finger protein 471 expression, functions, and molecular mechanisms in breast cancer.
[Clinical Epigenetics] |
|
|
|
| Investigators showed that the VEGF homolog encoded by Parapoxviruses, can induce cell proliferation, and alter the metabolism of breast cancer and normal breast cells, through alteration of MAPK-ERK and PI3K-AKT signaling.
[Cell Death & Disease] |
|
|
|
| To identify phosphatase and tensin homologue (PTEN) synthetic lethal interactions, TCGA analysis coupled with a whole-genome siRNA screen in isogenic PTEN-negative and -positive cells were performed. Among the candidate genes essential for the survival of PTEN-inactive TNBC cells, WDHD1 (WD repeat and high-mobility group box DNA-binding protein 1) expression was increased in the low vs. high PTEN TNBC samples.
[Cell Death & Disease] |
|
|
|
| Using Western blotting and qRT-PCR analyses, the authors revealed that in the T47D and BT20 breast cancer cell lines, astaxanthin inhibited expression of pontin and mutp53, as well as the Oct4 and Nanog cancer stem cell stemness genes.
[Marine Drugs] |
|
|
|
| Researchers created a lentiviral vector that allowed the autophagosome and autolysosome content of transduced cells to be monitored at the single-cell level. Purified subsets of normal human mammary cells showed that both the luminal progenitor-containing subset and the basal cells displayed highly variable but overall similar autophagic flux activity despite differences suggested by measurements of the proteins responsible in bulk lysates.
[Scientific Reports] |
|
|
|
| Scientists described a novel cancer-suppressing mechanism, via the secretion of bioactive factors by mammary cells, that was present in domesticated mammals with a low mammary cancer incidence.
[Scientific Reports] |
|
|
|
| Investigators report the design of a fully retargeted oncolytic herpes simplex virus for preferential infection of breast cancer cells through virus recognition of GFRα1, the cellular receptor for glial cell-derived neurotrophic factor .
[International Journal of Molecular Sciences] |
|
|
|
|
| The authors summarize the main findings concerning the relationship between Wnt signaling and breast cancer and provide an overview of existing mechanisms, challenges, and potential opportunities for advancing the therapy and diagnosis of breast cancer.
[Molecular Cancer] |
|
|
|
| Invesitgators provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.
[British Journal of Cancer] |
|
|
|
|
| Anixa Biosciences, Inc. announced that an Investigational New Drug (IND) application for its prophylactic breast cancer vaccine had been filed with the FDA.
[Anixa Biosciences, Inc.] |
|
|
|
| Phoenix Molecular Designs announced that the first patient has been dosed in their Phase Ib clinical trial of PMD-026. This RSK targeting trial was a first of its kind in the battle to combat the most aggressive subtype of breast cancer, known as TNBC.
[Phoenix Molecular Designs (PR Newswire LLC)] |
|
|
|
|
| May 16 – May 21, 2021
Lucca, Italy |
|
|
|
|
|
| | BC Cancer Research Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | The University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Georgetown University – Washington, DC, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
